Logo image of ALLO

ALLOGENE THERAPEUTICS INC (ALLO) Stock Fundamental Analysis

NASDAQ:ALLO - Nasdaq - US0197701065 - Common Stock - Currency: USD

2.255  -0.35 (-13.27%)

Premarket: 2.33 +0.08 (+3.33%)

Fundamental Rating

3

Taking everything into account, ALLO scores 3 out of 10 in our fundamental rating. ALLO was compared to 571 industry peers in the Biotechnology industry. While ALLO has a great health rating, there are worries on its profitability. ALLO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALLO has reported negative net income.
In the past year ALLO has reported a negative cash flow from operations.
ALLO had negative earnings in each of the past 5 years.
In the past 5 years ALLO always reported negative operating cash flow.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -89.10%, ALLO is doing worse than 71.58% of the companies in the same industry.
The Return On Equity of ALLO (-113.19%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -89.1%
ROE -113.19%
ROIC N/A
ROA(3y)-38.79%
ROA(5y)-32.49%
ROE(3y)-47.3%
ROE(5y)-38.88%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

ALLO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -100K -200K -300K

More info and screens

7

2. Health

2.1 Basic Checks

ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALLO has more shares outstanding
Compared to 5 years ago, ALLO has more shares outstanding
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -4.23, we must say that ALLO is in the distress zone and has some risk of bankruptcy.
ALLO has a Altman-Z score (-4.23) which is in line with its industry peers.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.23
ROIC/WACCN/A
WACC9.56%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

ALLO has a Current Ratio of 9.35. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
ALLO's Current ratio of 9.35 is fine compared to the rest of the industry. ALLO outperforms 77.80% of its industry peers.
A Quick Ratio of 9.35 indicates that ALLO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.35, ALLO is in the better half of the industry, outperforming 77.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.35
Quick Ratio 9.35
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

ALLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.93%, which is quite impressive.
Looking at the last year, ALLO shows a very negative growth in Revenue. The Revenue has decreased by -35.00% in the last year.
EPS 1Y (TTM)33.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.51%
Revenue 1Y (TTM)-35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 13.48% on average over the next years. This is quite good.
Based on estimates for the next years, ALLO will show a very strong growth in Revenue. The Revenue will grow by 375.05% on average per year.
EPS Next Y30.93%
EPS Next 2Y14.35%
EPS Next 3Y8.04%
EPS Next 5Y13.48%
Revenue Next Year-53.17%
Revenue Next 2Y-40.37%
Revenue Next 3Y-32.01%
Revenue Next 5Y375.05%

3.3 Evolution

ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.
Also next year ALLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y8.04%

More info and screens

0

5. Dividend

5.1 Amount

ALLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (2/20/2025, 8:00:00 PM)

Premarket: 2.33 +0.08 (+3.33%)

2.255

-0.35 (-13.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners67.46%
Inst Owner Change15.26%
Ins Owners7.07%
Ins Owner Change2.24%
Market Cap472.81M
Analysts81.82
Price Target9.41 (317.29%)
Short Float %22.18%
Short Ratio9.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.98%
Min EPS beat(2)1.21%
Max EPS beat(2)4.75%
EPS beat(4)4
Avg EPS beat(4)5.27%
Min EPS beat(4)1.21%
Max EPS beat(4)8.99%
EPS beat(8)7
Avg EPS beat(8)7.8%
EPS beat(12)11
Avg EPS beat(12)8.9%
EPS beat(16)15
Avg EPS beat(16)10.3%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-21.99%
Min Revenue beat(4)-100%
Max Revenue beat(4)124.67%
Revenue beat(8)4
Avg Revenue beat(8)79.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.05%
PT rev (3m)-3.8%
EPS NQ rev (1m)-1.61%
EPS NQ rev (3m)2.8%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)8.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4041.08
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS2.21
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.1%
ROE -113.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.79%
ROA(5y)-32.49%
ROE(3y)-47.3%
ROE(5y)-38.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.41%
Cap/Sales 523.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.35
Quick Ratio 9.35
Altman-Z -4.23
F-Score2
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)84.08%
Cap/Depr(5y)426.61%
Cap/Sales(3y)1271.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.51%
EPS Next Y30.93%
EPS Next 2Y14.35%
EPS Next 3Y8.04%
EPS Next 5Y13.48%
Revenue 1Y (TTM)-35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-53.17%
Revenue Next 2Y-40.37%
Revenue Next 3Y-32.01%
Revenue Next 5Y375.05%
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.73%
EBIT Next 3Y-0.81%
EBIT Next 5Y1.54%
FCF growth 1Y-4.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.6%
OCF growth 3YN/A
OCF growth 5YN/A